Triglyceride Treatment in the Age of Cholesterol Reduction

Progress in Cardiovascular Diseases

Volumn 59, Issue 2, 2016, Pages 107-118

  Agrawal, Nidhi ^a   Freitas Corradi, Patricia ^a   Gumaste, Namrata ^a   Goldberg, Ira J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Hyperlipidemia; Hypertriglyceridemia; Triglyceride

Indexed keywords

ALCOHOL; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; NICOTINIC ACID; OXPRENOLOL; PINDOLOL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EXERCISE; GENE LOCUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOATROPHY; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PATHOGENESIS; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE MANAGEMENT; METABOLISM;

CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; TRIGLYCERIDES;

EID: 84995579252     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2016.08.003     Document Type: Review

References (117)

1. 1. Goldberg, IJ, Hypertriglyceridemia: impact and treatment. Endocrinol Metab Clin North Am 38 (2009), 137–149.
2. 2. Merkel, M, Eckel, RH, Goldberg, IJ, Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43 (2002), 1997–2006.
3. 3. Dijk, W, Kersten, S, Regulation of lipid metabolism by angiopoietin-like proteins. Curr Opin Lipidol 27 (2016), 249–256.
4. 4. Goldberg, IJ, Eckel, RH, Abumrad, NA, Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res 50 (2009), S86–S90 [Suppl.].
5. 5. Surendran, RP, Visser, ME, Heemelaar, S, Wang, J, Peter, J, Defesche, JC, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 272 (2012), 185–196.
6. 6. Myocardial Infarction, G, Investigators, CAEC, Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med, 2016.
7. 7. Havel, RJ, Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man. Metabolism 10 (1961), 1031–1034.
8. 8. Brunzell, JD, Hazzard, WR, Porte, D Jr., Bierman, EL, Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 52 (1973), 1578–1585.
9. 9. Goldstein, JL, Hazzard, WR, Schrott, HG, Bierman, EL, Motulsky, AG, Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 52 (1973), 1533–1543.
10. 10. Benlian, P, De Gennes, JL, Foubert, L, Zhang, H, Gagne, SE, Hayden, M, Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 335 (1996), 848–854.
11. 11. Wittekoek, ME, Pimstone, SN, Reymer, PW, Feuth, L, Botma, GJ, Defesche, JC, et al. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 97 (1998), 729–735.
12. 12. Wittrup, HH, Tybjaerg-Hansen, A, Abildgaard, S, Steffensen, R, Schnohr, P, Nordestgaard, BG, A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 99 (1997), 1606–1613.
13. 13. Brunzell, JD, Davidson, M, Furberg, CD, Goldberg, RB, Howard, BV, Stein, JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51 (2008), 1512–1524.
14. 14. Burkhardt, R, Toh, SA, Lagor, WR, Birkeland, A, Levin, M, Li, X, et al. Trib 1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest 120 (2010), 4410–4414.
15. 15. Fisher, RM, Humphries, SE, Talmud, PJ, Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 135 (1997), 145–159.
16. 16. Shachter, NS, Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12 (2001), 297–304.
17. 17. Gordts, P, Nock, R, Son, N, Ramms, B, Lew, I, Gonzales, J, et al. ApoC-III modulates clearance of triglyceride-rich lipoproteins in mice through low density lipoprotein family receptors. J Clin Invest, 2016 [accepted for publication].
18. 18. TG, HDL Working Group of the Exome Sequencing Project NHL, Blood I, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371 (2014), 22–31.
19. 19. Sacks, FM, Alaupovic, P, Moye, LA, Cole, TG, Sussex, B, Stampfer, MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102 (2000), 1886–1892.
20. 20. Zilversmit, DB, A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res 33 (1973), 633–638.
21. 21. Yla-Herttuala, S, Lipton, BA, Rosenfeld, ME, Goldberg, IJ, Steinberg, D, Witztum, JL, Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A 88 (1991), 10143–10147.
22. 22. Rutledge, JC, Mullick, AE, Gardner, G, Goldberg, IJ, Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL. Circ Res 86 (2000), 768–773.
23. 23. Rutledge, JC, Woo, MM, Rezai, AA, Curtiss, LK, Goldberg, IJ, Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products. Circ Res 80 (1997), 819–828.
24. 24. Fellin, R, Baggio, G, Poli, A, Augustin, J, Baiocchi, MR, Baldo, G, et al. Familial lipoprotein lipase and apolipoprotein C-II deficiency. Lipoprotein and apoprotein analysis, adipose tissue and hepatic lipoprotein lipase levels in seven patients and their first degree relatives. Atherosclerosis 49 (1983), 55–68.
25. 25. Babirak, SP, Iverius, PH, Fujimoto, WY, Brunzell, JD, Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis 9 (1989), 326–334.
26. 26. Goldberg, IJ, Blaner, WS, Vanni, TM, Moukides, M, Ramakrishnan, R, Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys. J Clin Invest 86 (1990), 463–473.
27. 27. Rashid, S, Watanabe, T, Sakaue, T, Lewis, GF, Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36 (2003), 421–429.
28. 28. Goldberg, IJ, Le, NA, Paterniti, JR Jr., Ginsberg, HN, Lindgren, FT, Brown, WV, Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J Clin Invest 70 (1982), 1184–1192.
29. 29. Hokanson, JE, Austin, MA, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996), 213–219.
30. 30. Abdel-Maksoud, M, Sazonov, V, Gutkin, SW, Hokanson, JE, Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. J Cardiovasc Pharmacol 51 (2008), 331–351.
31. 31. Sarwar, N, Danesh, J, Eiriksdottir, G, Sigurdsson, G, Wareham, N, Bingham, S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262, 525 participants in 29 western prospective studies. Circulation 115 (2007), 450–458.
32. 32. Stalenhoef, AF, de Graaf, J, Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 19 (2008), 355–361.
33. 33. Kirchmair, R, Ebenbichler, CF, Patsch, JR, Post-prandial lipaemia. Baillieres Clin Endocrinol Metab 9 (1995), 705–719.
34. 34. Chan, DC, Pang, J, Romic, G, Watts, GF, Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep, 15, 2013, 309.
35. 35. Patsch, W, Esterbauer, H, Foger, B, Patsch, JR, Postprandial lipemia and coronary risk. Curr Atheroscler Rep 2 (2000), 232–242.
36. 36. Patsch, JR, Prasad, S, Gotto, AM Jr., Bengtsson-Olivecrona, G, Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. J Clin Invest 74 (1984), 2017–2023.
37. 37. Ginsburg, GS, Safran, C, Pasternak, RC, Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with “desirable” total cholesterol levels. Am J Cardiol 68 (1991), 187–192.
38. 38. Lamarche, B, Lemieux, I, Despres, JP, The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25 (1999), 199–211.
39. 39. Goldberg, IJ, Mazlen, RG, Rubenstein, A, Gibson, JC, Paterniti, JR Jr, Lindgren, FT, et al. Plasma lipoprotein abnormalities associated with acquired hepatic triglyceride lipase deficiency. Metabolism 34 (1985), 832–835.
40. 40. Campos, H, Khoo, C, Sacks, FM, Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans. Atherosclerosis 181 (2005), 345–351.
41. 41. Otvos, JD, Mora, S, Shalaurova, I, Greenland, P, Mackey, RH, Goff, DC Jr., Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 5 (2011), 105–113.
42. 42. St-Pierre, AC, Cantin, B, Dagenais, GR, Maurieg, P, Bernard, PM, Despres, JP, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec cardiovascular study. Arterioscler Thromb Vasc Biol 25 (2005), 553–559.
43. 43. Shimano, H, Arai, H, Harada-Shiba, M, Ueshima, H, Ohta, T, Yamashita, S, et al. Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb 15 (2008), 116–121.
44. 44. Kimura, T, Tse, K, Sette, A, Ley, K, Vaccination to modulate atherosclerosis. Autoimmunity 48 (2015), 152–160.
45. 45. Goldstein, JL, Schrott, HG, Hazzard, WR, Bierman, EL, Motulsky, AG, Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 (1973), 1544–1568.
46. 46. Pajukanta, P, Nuotio, I, Terwilliger, JD, Porkka, KV, Ylitalo, K, Pihlajamaki, J, et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 18 (1998), 369–373.
47. 47. Mar, R, Pajukanta, P, Allayee, H, Groenendijk, M, Dallinga-Thie, G, Krauss, RM, et al. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ Res 94 (2004), 993–999.
48. 48. Johansen, CT, Wang, J, Lanktree, MB, McIntyre, AD, Ban, MR, Martins, RA, et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 31 (2011), 1916–1926.
49. 49. Johansen, CT, Kathiresan, S, Hegele, RA, Genetic determinants of plasma triglycerides. J Lipid Res 52 (2011), 189–206.
50. 50. Johansen, CT, Wang, J, Lanktree, MB, Cao, H, McIntyre, AD, Ban, MR, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 42 (2010), 684–687.
51. 51. Rashid, S, Uffelman, KD, Lewis, GF, The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 16 (2002), 24–28.
52. 52. Wu, L, Parhofer, KG, Diabetic dyslipidemia. Metabolism 63 (2014), 1469–1479.
53. 53. Garcia-Arcos, I, Hiyama, Y, Drosatos, K, Bharadwaj, KG, Hu, Y, Son, NH, et al. Adipose-specific lipoprotein lipase deficiency more profoundly affects brown than white fat biology. J Biol Chem 288 (2013), 14046–14058.
54. 54. Joseph, J, Shamburek, RD, Cochran, EK, Gorden, P, Brown, RJ, Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. J Clin Endocrinol Metab 99 (2014), E1676–E1680.
55. 55. Weissglas-Volkov, D, Pajukanta, P, Genetic causes of high and low serum HDL-cholesterol. J Lipid Res 51 (2010), 2032–2057.
56. 56. Hegele, RA, Premature atherosclerosis associated with monogenic insulin resistance. Circulation 103 (2001), 2225–2229.
57. 57. Murase, T, Uchimura, H, A selective decline of postheparin plasma hepatic triglyceride lipase in hypothyroid rats. Metabolism 29 (1980), 797–801.
58. 58. Applebaum, DM, Goldberg, AP, Pykalisto, OJ, Brunzell, JD, Hazzard, WR, Effect of estrogen on post-heparin lipolytic activity. Selective decline in hepatic triglyceride lipase. J Clin Invest 59 (1977), 601–608.
59. 59. Dashti, N, Kelley, JL, Thayer, RH, Ontko, JA, Concurrent inductions of avian hepatic lipogenesis, plasma lipids, and plasma apolipoprotein B by estrogen. J Lipid Res 24 (1983), 368–380.
60. 60. Klop, B, Do Rego AT, Cabezas MC. Alcohol and plasma triglycerides. Curr Opin Lipidol 24 (2013), 321–326.
61. 61. Van de Wiel, A, The effect of alcohol on postprandial and fasting triglycerides. Int J Vasc Med, 2012, 2012, 862504.
62. 62. Grimm, RH Jr., Antihypertensive therapy: taking lipids into consideration. Am Heart J 122 (1991), 910–918.
63. 63. Weidmann, P, de Courten, M, Ferrari, P, Bohlen, L, Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol 22:Suppl. 6 (1993), S98–105.
64. 64. Weidmann, P, de Courten, M, Ferrari, P, Effect of diuretics on the plasma lipid profile. Eur Heart J 13:Suppl. G (1992), 61–67.
65. 65. Lehtonen, A, Effect of beta blockers on blood lipid profile. Am Heart J 109 (1985), 1192–1196.
66. 66. Krone, W, Nagele, H, Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 116 (1988), 1729–1734.
67. 67. Weidmann, P, Gerber, A, Mordasini, R, Effects of antihypertensive therapy on serum lipoproteins. Hypertension 5 (1983), III120–III131.
68. 68. Keane, WF, Tomassini, JE, Neff, DR, Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb 20 (2013), 123–133.
69. 69. Clement, LC, Mace, C, Avila-Casado, C, Joles, JA, Kersten, S, Chugh, SS, Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20 (2014), 37–46.
70. 70. Kaysen, GA, Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr 19 (2009), 73–77.
71. 71. Vaziri, ND, Norris, K, Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 31 (2011), 189–196.
72. 72. Stegmayr, B, Olivecrona, T, Olivecrona, G, Lipoprotein lipase disturbances induced by uremia and hemodialysis. Semin Dial 22 (2009), 442–444.
73. 73. Moradi, H, Vaziri, ND, Kashyap, ML, Said, HM, Kalantar-Zadeh, K, Role of HDL dysfunction in end-stage renal disease: a double-edged sword. J Ren Nutr 23 (2013), 203–206.
74. 74. Carr, A, Samaras, K, Thorisdottir, A, Kaufmann, GR, Chisholm, DJ, Cooper, DA, Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353 (1999), 2093–2099.
75. 75. Hadigan, C, Meigs, JB, Corcoran, C, Rietschel, P, Piecuch, S, Basgoz, N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32 (2001), 130–139.
76. 76. Periard, D, Telenti, A, Sudre, P, Cheseaux, JJ, Halfon, P, Reymond, MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation 100 (1999), 700–705.
77. 77. Lichtenstein, KA, Ward, DJ, Moorman, AC, Delaney, KM, Young, B, Palella, FJ, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15 (2001), 1389–1398.
78. 78. Grunfeld, C, Pang, M, Doerrler, W, Shigenaga, JK, Jensen, P, Feingold, KR, Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74 (1992), 1045–1052.
79. 79. Pillarisetti, S, Saxena, U, Lipoprotein lipase as a therapeutic target for dyslipidemia. Front Biosci 8 (2003), d238–d241.
80. 80. Semb, H, Peterson, J, Tavernier, J, Olivecrona, T, Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 262 (1987), 8390–8394.
81. 81. Lewis, GF, Rader, DJ, New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005), 1221–1232.
82. 82. Haim, M, Benderly, M, Boyko, V, Goldenberg, I, Tanne, D, Battler, A, et al. Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a bezafibrate infarction prevention substudy. Coron Artery Dis 17 (2006), 455–461.
83. 83. Jamshidi, Y, Flavell, DM, Hawe, E, MacCallum, PK, Meade, TW, Humphries, SE, Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis 163 (2002), 183–192.
84. 84. Rubins, HB, Robins, SJ, Collins, D, Fye, CL, Anderson, JW, Elam, MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999), 410–418.
85. 85. Wierzbicki, AS, FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 60 (2006), 442–449.
86. 86. Group AS, Ginsberg, HN, Elam, MB, Lovato, LC, Crouse, JR 3rd, Leiter, LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
87. 87. Ting, RD, Keech, AC, Drury, PL, Donoghoe, MW, Hedley, J, Jenkins, AJ, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study. Diabetes Care 35 (2012), 218–225.
88. 88. Investigators OT, Bosch, J, Gerstein, HC, Dagenais, GR, Diaz, R, Dyal, L, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367 (2012), 309–318.
89. 89. Kastelein, JJ, Maki, KC, Susekov, A, Ezhov, M, Nordestgaard, BG, Machielse, BN, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr lowering very high triglyceridEs (EVOLVE) trial. J Clin Lipidol 8 (2014), 94–106.
90. 90. Berglund, L, Brunzell, JD, Goldberg, AC, Goldberg, IJ, Sacks, F, Murad, MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97 (2012), 2969–2989.
91. 91. Brunzell, JD, Schrott, HG, The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. J Clin Lipidol 6 (2012), 409–412.
92. 92. Chait, A, Brunzell, JD, Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism 32 (1983), 209–214.
93. 93. Jellinger, PS, Dickey, RA, Ganda, OP, Mehta, AE, Nguyen, TT, Rodbard, HW, et al. AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract 6 (2000), 162–213.
94. 94. Stone, NJ, Robinson, JG, Lichtenstein, AH, Bairey Merz, CN, Blum, CB, Eckel, RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
95. 95. Berglund, L, Brunzell, JD, Goldberg, AC, Goldberg, IJ, Stalenhoef, A, Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab 28 (2014), 423–437.
96. 96. Havel, PJ, Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 63 (2005), 133–157.
97. 97. Graham, TE, Exercise, postprandial triacylglyceridemia, and cardiovascular disease risk. Can J Appl Physiol 29 (2004), 781–799.
98. 98. Chait, A, Brunzell, JD, Chylomicronemia syndrome. Adv Intern Med 37 (1992), 249–273.
99. 99. Tonelli, M, Collins, D, Robins, S, Bloomfield, H, Curhan, GC, Veterans' Affairs high-density lipoprotein intervention trial I. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66 (2004), 1123–1130.
100. 100. Ganji, SH, Tavintharan, S, Zhu, D, Xing, Y, Kamanna, VS, Kashyap, ML, Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 45 (2004), 1835–1845.
101. 101. Brown, BG, Zhao, XQ, Chait, A, Fisher, LD, Cheung, MC, Morse, JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001), 1583–1592.
102. 102. Musa-Veloso, K, Binns, MA, Kocenas, AC, Poon, T, Elliot, JA, Rice, H, et al. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Nutr Rev 68 (2010), 155–167.
103. 103. McKenney, JM, Sica, D, Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27 (2007), 715–728.
104. 104. Brinton, EA, Ballantyne, CM, Bays, HE, Kastelein, JJ, Braeckman, RA, Soni, PN, Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol, 12, 2013, 100.
105. 105. Heck, AM, Yanovski, JA, Calis, KA, Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20 (2000), 270–279.
106. 106. Tan, KC, Tso, AW, Tam, SC, Pang, RW, Lam, KS, Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med 19 (2002), 944–948.
107. 107. Hollander, PA, Elbein, SC, Hirsch, IB, Kelley, D, McGill, J, Taylor, T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21 (1998), 1288–1294.
108. 108. Yla-Herttuala, S, Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther 20 (2012), 1831–1832.
109. 109. Miller, N, Glybera and the future of gene therapy in the European Union. Nat Rev Drug Discov, 11, 2012, 419.
110. 110. Kersten, S, The genetics of dyslipidemia—when less is more. N Engl J Med 374 (2016), 1192–1193.
111. 111. Gaudet, D, Alexander, VJ, Baker, BF, Brisson, D, Tremblay, K, Singleton, W, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373 (2015), 438–447.
112. 112. Gaudet, D, Brisson, D, Tremblay, K, Alexander, VJ, Singleton, W, Hughes, SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371 (2014), 2200–2206.
113. 113. Jones, PH, Davidson, MH, Stein, EA, Bays, HE, McKenney, JM, Miller, E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 92 (2003), 152–160.
114. 114. Kastelein, JJ, Sager, PT, de Groot, E, Veltri, E, Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression (ENHANCE) trial. Am Heart J 149 (2005), 234–239.
115. 115. Ballantyne, CM, Bays, HE, Kastelein, JJ, Stein, E, Isaacsohn, JL, Braeckman, RA, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 110 (2012), 984–992.
116. 116. Bays, HE, Ballantyne, CM, Kastelein, JJ, Isaacsohn, JL, Braeckman, RA, Soni, PN, Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 108 (2011), 682–690.
117. 117. Teo, KK, Goldstein, LB, Chaitman, BR, Grant, S, Weintraub, WS, Anderson, DC, et al. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: impact on Global Health Outcome (AIM-HIGH) trial. Stroke 44 (2013), 2688–2693.